Posts

Argenx Acquires Forte Biosciences for $2.2 Billion to Add Phase 2‑Stage Vitiligo and Celiac Drug FB102 to Its Immunology Pipeline

on

Fate’s off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease

on

Boehringer Ingelheim partners with Immunai on $15M AI‑driven T‑cell collaboration

on

Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer

on

Bristol Myers Squibb and Bain Capital Launch New Autoimmune Disease Biotech Company

on

Miltenyi Bio's CAR-T Clears Triple Autoimmune Burden in Single Patient

on

Sanofi's $180 Million Investment in Kali Therapeutics for T-Cell Engager Development

on

Gilead Acquires Ouro Medicines for Up to $2.18 Billion to Advance T Cell Engager Autoimmune Therapies

on

Sanofi Inks $2.56 Billion Autoimmune Bispecific Deal with Earendil Labs

on

Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D., to Scientific Advisory Board

on

Dianthus Therapeutics Announces Proposed $400 Million Underwritten Public Offering (Upsized from Initial Plans)

on

Eli Lilly Acquires Orna Therapeutics for Up to $2.4 Billion to Advance In Vivo CAR-T Therapies

on

Lilly Invests $85M Upfront in Repertoire Immune Medicines for Autoimmune Therapies Partnership

on

Zag Bio Appoints Jan Hillson, M.D., as Chief Medical Officer

on

Lilly to acquire Ventyx Biosciences for ~$1.2B to add oral NLRP3 and other inflammatory drugs

on

Nektar Digs Into Mid-Stage Data To Establish Alopecia Efficacy of Rezpeg

on

Kyverna to seek FDA engagement after positive autoimmune CAR-T data in stiff person syndrome

on

Sanofi returns to Dren Bio for another B‑cell depletion therapy with $100M upfront

on

Ventus Therapeutics Doses First Patient in Phase 2 Trial of VENT-03, an Oral cGAS Inhibitor, in Lupus

on

Vera Therapeutics Appoints James R. Meyers to Its Board of Directors

on